Cialis vs Alprostadil (Caverject/MUSE): Long-Term Durability of Response

How Each Drug Works and Why Mechanism Predicts Durability

Tadalafil blocks phosphodiesterase type 5 (PDE5), preserving cyclic GMP and allowing smooth-muscle relaxation in response to sexual stimulation. Alprostadil is a synthetic prostaglandin E1 (PGE1) that directly activates adenylyl cyclase, raising cyclic AMP independently of any neural input. That mechanistic difference matters for durability: tadalafil requires intact nitric-oxide signaling to work, while alprostadil bypasses it entirely.

Why Mechanism Matters for Long-Term Use

Because tadalafil depends on endogenous NO release, men with severe neurogenic or vasculogenic ED who have lost most of that signaling pathway may see diminishing returns over years as their underlying condition progresses. Alprostadil, by contrast, can still produce an erection even in men with complete cavernous nerve injury, which is why it remains the standard second-line agent after radical prostatectomy. The FDA-approved labeling for Caverject notes this direct smooth-muscle action explicitly.

Receptor Downregulation: Does It Happen?

PDE5 receptors do not appear to downregulate with chronic tadalafil exposure. Long-term registry data and open-label extensions consistently show maintained or slightly improved IIEF scores over time, not erosion. Alprostadil's EP2/EP3 prostaglandin receptors show a theoretical desensitization risk with daily use, but clinical studies using 3 to 7 injections per week for up to 18 months found no statistically significant loss of per-injection efficacy. A Cochrane review of intracavernosal alprostadil concluded that efficacy was maintained across the study periods examined.

Tadalafil Long-Term Durability: What the Trial Data Show

The Brock et al. 2-Year Extension

The most rigorous long-term tadalafil dataset comes from Brock et al. (J Urol 2002), a 2-year open-label extension involving men who had completed earlier phase-III tadalafil trials. Brock et al. Found that the proportion of men achieving erections sufficient for intercourse remained stable across 24 months, with no evidence of diminishing drug effect. Mean IIEF erectile function domain scores at the 24-month mark were comparable to scores at month 3, and no dose escalation was required in the majority of participants. That stability is the single most clinically useful feature of tadalafil's long-term profile.

Daily vs. On-Demand Dosing and Durability

Daily tadalafil at 5 mg produces plasma trough levels sufficient to inhibit PDE5 continuously. A randomized controlled trial published in the Journal of Sexual Medicine showed that 12 months of once-daily tadalafil 5 mg produced sustained improvements in IIEF scores compared with placebo, with no attenuation at the 12-month endpoint. On-demand dosing at 10 to 20 mg shows identical pharmacodynamic behavior per dose through multi-year follow-up. Men on daily dosing also report a secondary benefit: spontaneous erections return in some patients, which may reflect a rehabilitative effect on cavernous oxygenation rather than simple pharmacological action.

Predictors of Response Maintenance

Age, glycemic control, and cardiovascular risk factor burden all predict whether a man will maintain response to tadalafil over 2+ years. Men with well-controlled type 2 diabetes on tadalafil showed slightly lower response rates at baseline (roughly 60 to 65% vs. 80% in non-diabetic cohorts) but did not show faster erosion of response over time in the available data. The American Urological Association guideline on erectile dysfunction lists PDE5 inhibitors as first-line therapy regardless of etiology, and notes that ongoing cardiovascular risk factor management is part of the treatment plan.

Alprostadil Long-Term Durability: Injection and Intraurethral Forms

Linet et al. NEJM 1996: The Foundational RCT

Linet and Ogrinc (N Engl J Med 1996) conducted the key multicenter double-blind RCT of intracavernosal alprostadil, enrolling 296 men with erectile dysfunction of organic or mixed origin. At the end of the 6-month study, 87% of injection attempts in the alprostadil arm resulted in erections sufficient for intercourse, compared with 24% in the placebo group (P<0.001). Penile pain occurred in 50% of men at some point during the study, though it was rated as mild in most cases. The trial was 6 months, so it does not directly address years-long durability, but it established the per-use efficacy benchmark that open-label extensions later tracked.

Open-Label Extension Data Beyond 6 Months

Open-label follow-up studies of intracavernosal alprostadil extending to 18 to 24 months confirm that per-injection success rates remain in the 70 to 85% range for men who continue using the drug. The key durability challenge is not pharmacological tolerance. It is dropout. Data compiled in a systematic review published via PubMed show that 30 to 50% of men discontinue intracavernosal alprostadil within the first year, with penile pain, partner discomfort, and injection anxiety driving most exits. Men who stay on the drug report stable efficacy.

MUSE (Intraurethral Alprostadil): Lower Efficacy, Lower Barrier

MUSE delivers 125 to 1000 mcg of alprostadil as a medicated urethral suppository. Per-use success rates in clinical trials are lower than for intracavernosal injection, ranging from 43% in unselected ED populations to 65% in men who were prospectively titrated in-office. The FDA-approved labeling for MUSE reports that in the phase III trial, 64.9% of patients had at least one successful intercourse attempt, compared with 18.6% of placebo patients. Long-term retention with MUSE is even lower than with injection, largely because the lower efficacy ceiling frustrates users who do not achieve satisfactory results after titration.

Dose Escalation Over Time

Some men using alprostadil injection long-term require dose increases, though this is not universal. A minority of patients who start at 10 mcg find themselves needing 20 to 30 mcg after 12 to 18 months. This may reflect disease progression (worsening vasculogenic ED) rather than true tachyphylaxis to alprostadil itself. Distinguishing the two is clinically important when deciding whether to escalate dose or switch therapy.

Head-to-Head Context: No Direct Long-Term RCT Exists

No published randomized controlled trial has placed tadalafil and intracavernosal alprostadil side by side for 24+ months with a shared primary endpoint. Comparisons draw on separate trial arms and open-label registries. With that limitation stated, the available evidence supports these practical conclusions:

• Tadalafil shows durable per-dose efficacy through 24 months with no pharmacological tolerance and a favorable discontinuation rate (typically below 20% at 12 months in clinical trials).
• Alprostadil injection shows stable per-use efficacy in men who continue using it, but real-world discontinuation rates of 30 to 50% at 12 months substantially reduce population-level durability.
• MUSE shows lower per-use efficacy than injection and similar or higher dropout.

A 2022 meta-analysis in the journal Andrology examined long-term PDE5 inhibitor use and found no signal of diminishing efficacy through the available follow-up periods, which extended to 3 years in some included studies.

When Alprostadil Outperforms Tadalafil Long-Term

Post-Prostatectomy Erectile Rehabilitation

After bilateral nerve-sparing radical prostatectomy, intracavernosal alprostadil produces erections in men who get no response from oral PDE5 inhibitors. The cavernous nerves, even if spared, remain functionally impaired for 6 to 24 months. Alprostadil bypasses that impairment. A prospective study published in the Journal of Urology found that penile rehabilitation with intracavernosal alprostadil started within 4 weeks of prostatectomy preserved cavernous smooth-muscle architecture and improved eventual return of natural erections compared with no treatment.

Severe Vasculogenic ED

Men with end-stage vasculogenic disease, including those with Leriche syndrome or severe diabetic angiopathy, may achieve <50% success rates with maximal-dose tadalafil. Alprostadil injection at 20 to 40 mcg can still produce reliable erections by directly driving smooth-muscle relaxation through the cyclic AMP pathway. For these men, alprostadil's durability profile is effectively superior because tadalafil stops working altogether rather than just partially declining.

PDE5-Inhibitor Contraindications

Men on nitrate therapy for angina cannot use any PDE5 inhibitor. Alprostadil has no nitrate interaction. The FDA labeling for tadalafil carries a contraindication for concurrent organic nitrate use due to risk of severe hypotension. For those patients, alprostadil is not merely a second-line option. It is the only oral-alternative-free pharmacological route to a drug-assisted erection.

When Tadalafil Outperforms Alprostadil Long-Term

Adherence-Adjusted Efficacy

Because tadalafil is oral, on-demand, and painless, adherence over 24 months is substantially higher than for alprostadil injection or MUSE. Adherence-adjusted efficacy, meaning the proportion of attempted sexual encounters that succeed when accounting for drug refusal or avoidance, favors tadalafil significantly in long-term real-world use. A man who never reaches for the needle misses 100% of the drug's benefit.

Psychogenic and Mixed-Etiology ED

Tadalafil's on-demand convenience means it can be used even when erections are intermittent and partially spontaneous, without the commitment and planning that injection requires. Men with predominantly psychogenic ED or mixed-etiology ED tend to respond better to tadalafil long-term, both because the NO-cGMP pathway is largely intact and because the lower procedural burden prevents injection anxiety from compounding their underlying issue.

Cardiovascular Risk Factor Management as Co-therapy

Daily tadalafil 5 mg has shown modest benefits on lower urinary tract symptoms (LUTS) through PDE5 inhibition in prostatic smooth muscle. A phase III trial published in the Journal of Urology (N=1,058) showed that tadalafil 5 mg daily improved both IIEF scores and International Prostate Symptom Scores compared with placebo after 12 weeks. For men with concurrent BPH and ED, tadalafil is the only agent with an FDA indication for both conditions simultaneously.

Switching From Cialis to Alprostadil: Protocols and Timing

Defining Treatment Failure Before Switching

The clinical threshold for declaring tadalafil failure is two unsuccessful attempts at the highest tolerated dose (20 mg on-demand or 5 mg daily for at least 4 weeks) taken under optimal conditions: adequate sexual stimulation, no concurrent alcohol above one standard drink, and administration at least 30 minutes before activity. Switching after only one attempt or a suboptimal trial wastes an effective therapy.

In-Office Titration for Alprostadil Injection

When switching to Caverject, the first injection must occur in a physician's office for dose titration and priapism monitoring. Starting doses by etiology:

• Psychogenic or neurogenic ED: 1.25 to 2.5 mcg
• Vasculogenic or mixed ED: 2.5 to 5 mcg
• Post-prostatectomy neurogenic ED: 1.25 mcg

The dose is titrated upward at each visit until a firm erection lasting no more than 60 minutes is achieved. The American Urological Association recommends this in-office titration protocol before self-injection is initiated, citing priapism risk at inappropriately high starting doses.

Combination Therapy as an Alternative to a Hard Switch

Some men with partial tadalafil response benefit more from combination therapy than from abandoning tadalafil entirely. Adding low-dose alprostadil injection (5 to 10 mcg) on top of daily tadalafil 5 mg can produce erections in men who fail either agent alone. This approach is off-label but is supported by mechanistic rationale (cGMP and cAMP pathways are additive) and small prospective series. Any combination must be supervised closely because hypotension risk is additive as well.

Safety Profile Comparison Over Long-Term Use

Tadalafil: 24-Month Safety

Common adverse effects with tadalafil, including headache, flushing, back pain, and myalgia, typically diminish after the first 4 to 8 weeks as patients accommodate to the drug. No organ-level toxicity has been documented through 3 years of continuous daily use. A long-term safety analysis of tadalafil published via PubMed found no new safety signals emerging beyond the first 12 weeks of use.

Alprostadil: 24-Month Safety

Penile fibrosis is the most clinically significant long-term risk of intracavernosal alprostadil. Published series report fibrosis rates of 2 to 8% with regular use over 12 to 18 months. Priapism, defined as erection lasting more than 4 hours, occurs in roughly 1% of injection attempts and requires emergency treatment to prevent permanent cavernous damage. The Linet et al. NEJM trial reported a 1.0% rate of prolonged erection requiring medical intervention. MUSE carries a risk of urethral burning and, rarely, syncope due to systemic hypotension.

Clinical Decision Framework: Tadalafil vs. Alprostadil for Long-Term Use

The following criteria guide which agent is likely to deliver better long-term durability for an individual patient:

Choose tadalafil first if:

• ED etiology is psychogenic, mixed, or mild-to-moderate vasculogenic
• Patient has intact nitric oxide signaling (responds to sexual stimulation with partial erection)
• BPH or LUTS co-exists
• Patient preference is strongly oral and on-demand
• No nitrate therapy is required

Choose alprostadil first (or after tadalafil failure) if:

• Post-prostatectomy, especially non-nerve-sparing or early recovery phase
• Severe vasculogenic ED with <50% response to 20 mg tadalafil
• Nitrate therapy contraindications PDE5 inhibitor use
• Penile rehabilitation protocol is indicated
• Prior adequate tadalafil trial has failed

Consider combination if:

• Partial response to tadalafil alone
• Unwilling to abandon oral therapy entirely
• Supervised setting allows safe dose titration